Hydroxychloroquine
- Generic Name
- Hydroxychloroquine
- Brand Names
- Plaquenil, Sovuna
- Drug Type
- Small Molecule
- Chemical Formula
- C18H26ClN3O
- CAS Number
- 118-42-3
- Unique Ingredient Identifier
- 4QWG6N8QKH
- Background
Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like chloroquine. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxi...
- Indication
Hydroxychloroquine is indicated for the prophylaxis of malaria where chloroquine resistance is not reported, treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax), chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.
- Associated Conditions
- Acute Rheumatoid Arthritis, Malaria, Porphyria Cutanea Tarda, Q Fever, Sjogren's Syndrome (SS), Systemic Lupus Erythematosus, Uncomplicated Malaria caused by Plasmodium Vivax, Uncomplicated Malaria caused by Plasmodium malariae, Uncomplicated Malaria caused by Plasmodium ovale, Chronic Discoid Lupus Erythematosus (DLE), Chronic Rheumatoid Arthritis, Uncomplicated Malaria caused by Plasmodium falciparum
- Associated Therapies
- -
Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Sanford Health
- Target Recruit Count
- 1
- Registration Number
- NCT04372017
- Locations
- 🇺🇸
Sanford Health, Sioux Falls, South Dakota, United States
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- St. Francis Hospital, New York
- Target Recruit Count
- 18
- Registration Number
- NCT04370782
- Locations
- 🇺🇸
St Francis Hospital, Roslyn, New York, United States
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- University Hospital, Lille
- Registration Number
- NCT04372082
Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.
- Conditions
- Interventions
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Services Institute of Medical Sciences, Pakistan
- Target Recruit Count
- 374
- Registration Number
- NCT04370015
Bacteriotherapy in the Treatment of COVID-19
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2020-05-04
- Lead Sponsor
- University of Roma La Sapienza
- Target Recruit Count
- 70
- Registration Number
- NCT04368351
- Locations
- 🇮🇹
Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy), Rome, Italy
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Fondation Hôpital Saint-Joseph
- Registration Number
- NCT04365582
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2020-04-28
- Lead Sponsor
- Roberto Poscia MD, PhD
- Target Recruit Count
- 152
- Registration Number
- NCT04366089
- Locations
- 🇮🇹
Francesco Pugliese, Rome, RM, Italy
Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-09-02
- Target Recruit Count
- 1700
- Registration Number
- NCT04363450
- Locations
- 🇺🇸
Lafayette General Medical Center, Lafayette, Louisiana, United States
🇺🇸University Hospital and Clinics, Lafayette, Louisiana, United States
Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Oregon Health and Science University
- Registration Number
- NCT04363866
- Locations
- 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)
- Conditions
- Interventions
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2021-02-12
- Target Recruit Count
- 2300
- Registration Number
- NCT04363827
- Locations
- 🇮🇹
Irst Irccs, Meldola, FC, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.